Evidence map›Paper›PMID 34494711›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2021

Relationships among tau burden, atrophy, age, and naming in the aphasic variant of Alzheimer's disease.

Adam Martersteck, Jaiashre Sridhar, Christina Coventry, Sandra Weintraub, M-Marsel Mesulam, Emily Rogalski

Open access · greenAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Atypical Presentations of Alzheimer Disease.Continuum (Minneapolis, Minn.) · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Adam MartersteckMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University (NU) Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0001-6997-9390
Jaiashre SridharMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University (NU) Feinberg School of Medicine, Chicago, Illinois, USA.
Christina CoventryMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University (NU) Feinberg School of Medicine, Chicago, Illinois, USA.
Sandra WeintraubMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University (NU) Feinberg School of Medicine, Chicago, Illinois, USA.
M-Marsel MesulamMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University (NU) Feinberg School of Medicine, Chicago, Illinois, USA.
Emily RogalskiMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University (NU) Feinberg School of Medicine, Chicago, Illinois, USA.
Northwestern University · US

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROGALSKI, EMILY J · 1996 to 2020
$28.9M
Research Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SANDRA WEINTRAUB · 2021 to 2026
$26.3M
PREDOCTORAL AND POSTDOCTORAL TRAINING PROGRAM IN AGING AND DEMENTIAT32AG020506 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROBERT J VASSAR, SANDRA WEINTRAUB · 2002 to 2026
$9.9M
Language in Primary Progressive AphasiaR01DC008552 · NIDCD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MESULAM, MAREK-MARSEL M · 2007 to 2021
$8.5M
Determinants of neurodegenerative decline in the aphasic variant of Alzheimer's diseaseR01AG056258 · NIA · UNIVERSITY OF CHICAGO · PI ROGALSKI, EMILY J · 2017 to 2022
$4.1M
Determinants of Neurodegenerative Decline in Primary Progressive AphasiaR01NS075075 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROGALSKI, EMILY J · 2012 to 2016
$1.7M
NCATS NIH HHS UL1 TR001422NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG072977NIA NIH HHS R01 AG056258NIA NIH HHS T32 AG020506NIDCD NIH HHS R01 DC008552NINDS NIH HHS R01 NS075075
6 · The paper itself

Abstract

introductionExamination of pathologic, anatomic, and cognitive relationships has been limited in primary progressive aphasia (PPA) with underlying Alzheimer's disease (AD) neuropathology.

methodsSpatial relationships between tau positron emission tomography (PET), cortical thickness, age, and naming on the Boston Naming Test (BNT) in PPA with biomarker evidence of AD (PPA-AD) were examined.

resultsHigher tau PET burden was associated with atrophy and younger age. There was a significant left-lateralized relationship between lower BNT and more atrophy, and between lower BNT and increased tau burden. Variance in naming was primarily shared between tau and atrophy (51%), but naming was uniquely explained more by atrophy (32%) than tau (16%). Higher left anterior temporal tau burden was associated with greater 1-year rate of decline in naming. DISCUSSION: PPA-AD has a similar relationship between abnormal biomarkers as first described in amnestic AD, with differing spatial extent, reflecting the left-lateralized nature of the language network.

Indexed as

Aphasia, Primary ProgressiveAgedAge FactorsAlzheimer DiseaseAtrophyBrainBrain Cortical ThicknessFemaleHumansLanguage TestsMalePositron-Emission Tomographytau ProteinsTemporal Lobetau ProteinsatrophyAV-1451cortical thicknessmagnetic resonance imagingnamingpositron emission tomographyprimary progressive aphasiatau positron emission tomographyvolumetric magnetic resonance imaging

Identifiers

PMID34494711
PMCPMC8648928
OpenAlexW3196791175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.